A phase I study to evaluate the safety and efficacy of LV305 combined with KEYTRUDA (pembrolizumab) in patients with melanoma
Latest Information Update: 13 Aug 2015
At a glance
- Drugs LV 305 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 13 Aug 2015 New trial record